Trypanosoma cruzi targets for new chemotherapeutic approaches

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 1, 2009, Pages 105-121

  Soeiro, Maria Nazaré C ^a   De Castro, Solange L ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Chagas disease; Chemotherapy; Drug targets; Trypanosoma cruzi

Indexed keywords

2 [2 (2,4 DIFLUOROPHENYL) 2 HYDROXY 1 METHYL 3 (1H 1,2,4 TRIAZOL 1 YL)PROPYL] 4 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL] 1,2,4 TRIAZOL 3(2H) ONE; 2,5 BIS(4 AMIDINOPHENYL)FURAN; 22,26 AZASTEROL; 5,9,13 TRIMETHYL 4,8,12 TETRADECATRIEN 1 YLPYRIDINIUM; ALBACONAZOLE; ALENDRONIC ACID; ALLOPURINOL; AMIODARONE; ANTITRYPANOSOMAL AGENT; BENZNIDAZOLE; BSM 207147; DB 1362; DB 569; DB 889; E 5700; FLUCONAZOLE; GERANYLTRANSFERASE; ITRACONAZOLE; KETOCONAZOLE; LANOSTEROL SYNTHASE; MEVINOLIN; NIFURTIMOX; PAFURAMIDINE; PAMIDRONIC ACID; PENTAMIDINE; POSACONAZOLE; QUINUCLIDINE; RAVUCONAZOLE; RISEDRONIC ACID; SQUALENE DERIVATIVE; SQUALENE SYNTHASE; TERBINAFINE; UMBELLIFERONE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WC 9; STEROL;

AFRICAN TRYPANOSOMIASIS; AREA UNDER THE CURVE; CHAGAS DISEASE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG STRUCTURE; HUMAN; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NUCLEOTIDE METABOLISM; REVIEW; STEROL METABOLISM; TRYPANOSOMA CRUZI; ANIMAL; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; METABOLISM; PENTOSE PHOSPHATE CYCLE;

ANIMALS; DRUG EVALUATION, PRECLINICAL; PENTOSE PHOSPHATE PATHWAY; STEROLS; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 61449562202     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728220802623881     Document Type: Review

References (142)

1. Reddy M, Gill SS, Kalkar SR, et al. Oral drug therapy for multiple neglected tropical diseases: a systematic review. JAMA 2007;298:1911-1924 (Pubitemid 350005235)
2. Dias JC. Globalization, inequity and Chagas disease. Cad Saude Publica 2007;23:13-22
3. Schmunis GA. Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem Inst Oswaldo Cruz 2007;102 (Suppl 1):75-85 (Pubitemid 350146006)
4. WHO. Control of Chagas Disease. Technical Reports Series 2002;905:1-109
5. Dias JC, Prata A, Correia D. Problems and perspectives for Chagas disease control: in search of a realistic analysis. Rev Soc Bras Med Trop 2008;41:193-196 (Pubitemid 351872401)
6. Bilate AM, Cunha-Neto E. Chagas disease cardiomyopathy: current concepts of an old disease. Rev Inst Med Trop Sao Paulo 2008;50:67-74 (Pubitemid 351744065)
7. Tarleton RL, Reithinger R, Urbina JA, et al. The challenges of Chagas Disease - grim outlook or glimmer of hope. PLoS Med 2007;4;e332. Published online 27 December 2007, doi: 10.1371/journal. pmed.0040332
8. Rocha MO, Teixeira MM, Ribeiro AL. An update on the management of Chagas cardiomyopathy. Expert Rev Anti Infect Ther 2007;5:727-743 (Pubitemid 47250142)
9. Coura JR, de Castro SL. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 2002;97:3-24 (Pubitemid 135746197)
10. Filardi LS, Brener Z. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R Soc Trop Med Hyg 1987;81:755-759 (Pubitemid 18070985)
11. Marin-Neto JA, Rassi A Jr, Morillo CA, et al. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy:the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J 2008;156:37-43 (Pubitemid 351862295)
12. Viotti R, Vigliano C. Etiological treatment of chronic Chagas disease:neglected evidence by evidence-based medicine. Expert Rev Anti Infect Ther 2007;5:717-726 (Pubitemid 47250141)
13. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment:a nonrandomized trial. Ann Intern Med 2006;144:724-734 (Pubitemid 46780632)
14. Heby O, Persson L, Rentala M. Targeting the polyamine biosynthetic enzymes: a promising approach to therapy of African sleeping sickness, Chagas' disease, and leishmaniasis. Amino Acids 2007;33:359-366
15. Gonzalez-Perdomo M, De Castro SL, Meirelles MNL, et al. Trypanosoma cruzi proliferation and differentiation is blocked by topoisomerase II inhibitors. Antimicrob Agents Chemother 1990;34:1707-1714 (Pubitemid 20259498)
16. Fragoso SP, Mattei D, Hines JC, et al. Expression and cellular localization of Trypanosoma cruzi type II DNA topoisomerase. Mol Biochem Parasitol 1998;94:197-204 (Pubitemid 28377286)
17. Neres J, Bryce RA, Douglas KT. Rational drug design in parasitology:trans-sialidase as a case study for Chagas disease. Drug Discov Today 2008;13:110-117
18. Chamond N, Goytia M, Coatnoan N, et al. Trypanosoma cruzi proline racemases are involved in parasite differentiation and infectivity. Mol Microbiol 2005;58:46-60 (Pubitemid 41415030)
19. Steverding D, Tyler KM. Novel antitrypanosomal agents. Expert Opin Investig Drugs 2005;14:939-955
20. Linares GEG, Ravaschino EL, Rodriguez JB. Progresses in the field of drug design to combat tropical protozoan parasitic diseases. Curr Med Chem 2006;13:335-360
21. Maya JD, Cassels BK, Iturriaga-Vasquez P, et al. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp Biochem Physiol A Mol Integr Physiol 2007;146:601-620 (Pubitemid 46341910)
22. Duschak VG, Couto AS. An insight on targets and patented drugs for chemotherapy of Chagas disease. Recent Patents Anti-Infect Drug Discov 2007;2:19-51 (Pubitemid 46729086)
23. Urbina JA. Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites. Parasitology 1997;114 (Suppl):S91-9 (Pubitemid 27397867)
24. Urbina JA. Specific treatment of Chagas disease:current status and new developments. Curr Opin Infect Dis 2001;14:733-741 (Pubitemid 33141196)
25. Urbina JA. New chemotherapeutic approaches for the treatment of Chagas disease (American Trypanosomiasis). Expert Opin Ther Patents 2003;13:661-669 (Pubitemid 36622219)
26. Buckner FS. Sterol 14-demethylase inhibitors for Trypanosoma cruzi infections. Adv Exp Med Biol 2008;625:61-80
27. Peñna-Díaz J, Montalvetti A, Flores CL, et al. Mitochondrial localization of the mevalonate pathway enzyme 3-hydroxy-3- methyl-glutaryl-CoA reductase in trypanosomatidae. Mol Biol Cell 2004;15:1356-1363 (Pubitemid 38316241)
28. Florin-Christensen M, Florin-Christensen J, Garin C, et al. Inhibition of Trypanosoma cruzi growth and sterol biosynthesis by lovastatin. Biochem Biophys Res Commun 1990;166:1441-1445 (Pubitemid 20069002)
29. Urbina JA, Lazardi K, Marchan E, et al. Mevinolin (lovastatin) potentiates the antiproliferative effects of ketoconazole and terbinafine against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob Agents Chemother 1993;37:580-591 (Pubitemid 23072606)
30. Garzoni LR, Caldera A, Meirelles MN, et al. Selective in vitro effects of the farnesyl pyrophosphate synthase inhibitor risedronate on Trypanosoma cruzi. Int J Antimicrob Agents 2004;23:273-285 (Pubitemid 38283597)
31. Garzoni LR, Waghabi MC, Baptista MM, et al. Antiparasitic activity of risedronate in a murine model of acute Chagas' disease. Int J Antimicrob Agents 2004b;23:286-290 (Pubitemid 38283598)
32. Bouzahzah B, Jelicks LA, Morris SA, et al. Risedronate in the treatment of murine Chagas' disease. Parasitol Res 2005;96:184-187 (Pubitemid 40869050)
33. Martin MB, Grimley JS, Lewis JC, et al. Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum:a potential route to chemotherapy. J Med Chem 2001;44:909-916 (Pubitemid 32861615)
34. Szajnman SH, Ravaschino EL, Docampo R, et al. Synthesis and biological evaluation of 1-amino-1,1-bisphosphonates derived from fatty acids against Trypanosoma cruzi targeting farnesyl pyrophosphate synthase. Bioorg Med Chem Lett 2005;15:4685-4690 (Pubitemid 41356662)
35. Szajnman SH, Garcia Linares GE, Li ZH, et al. Synthesis and biological evaluation of 2-alkylaminoethyl-1,1-bisphosphonic acids against Trypanosoma cruzi and Toxoplasma gondii targeting farnesyl diphosphate synthase. Bioorg Med Chem 2008;16:3283-3290
36. DoCampo R, Moreno SNJ. Bisphosphonates as chemotherapeutic agents against trypanosomatids and Apicomplexan parasites. Curr Drug Targets-Infect Dis 2001;1:51-61
37. Ferella M, Li ZH, Andersson B, et al. Farnesyl diphosphate synthase localizes to the cytoplasm of Trypanosoma cruzi and Trypanosoma brucei. Exp Parasitol 2008;119:308-312
38. Gabelli SB, McLellan JS, Montalvetti A, et al. Structure and mechanism of the farnesyl diphosphate synthase from Trypanosoma cruzi: implications for drug design. Proteins 2006;62:80-88 (Pubitemid 43063006)
39. Urbina JA, Concepcion JL, Rangel S, et al. Squalene synthase as a chemotherapeutic target in Trypanosoma cruzi and Leishmania mexicana. Mol Biochem Parasitol 2002;125:35-45 (Pubitemid 35449244)
40. Urbina JA, Concepcion JL, Montalvetti A, et al. Mechanism of action of 4-phenoxyphenoxyethyl thiocyanate (WC-9) against Trypanosoma cruzi, the causative agent of Chagas' disease. Antimicrob Agents Chemother 2003a;47:2047-2050 (Pubitemid 36637844)
41. Elhalem E, Bailey BN, Docampo R, et al. Design, synthesis, and biological evaluation of aryloxyethyl thiocyanate derivatives against Trypanosoma cruzi. J Med Chem 2002;45:3984-3999 (Pubitemid 35024300)
42. Braga MV, Urbina JA, De Souza W. Effects of squalene synthase inhibitors on the growth and ultrastructure of Trypanosoma cruzi. Int J Antimicrobial Agents 2004;24:72-78 (Pubitemid 38844566)
43. Urbina JA, Concepcion JL, Caldera A, et al. In vitro and in vivo activities of E5700 and ER-119884, two novel orally active squalene synthase inhibitors, against Trypanosoma cruzi. Antimicrob Agents Chemother 2004;48:2379-2387
44. Sealey-Cardona M, Cammerer S, Jones S, et al. Kinetic characterization of squalene synthase from Trypanosoma cruzi: selective inhibition by quinuclidine derivatives. Antimicrob Agents Chemother 2007;51:2123-2129 (Pubitemid 46903104)
45. Orenes-Lorente LS, Gomez R, Jimenez C, et al. Biphenylquinuclidines as inhibitors of squalene synthase and growth of parasitic protozoa. Bioorg Med Chem 2005;13:3519-3529 (Pubitemid 40545807)
46. Maldonado RA, Molina J, Payares G, et al. Experimental chemotherapy with combinations of ergosterol biosynthesis inhibitors in murine models of Chagas' disease. Antimicrob Agents Chemother 1993;37:1353-1359 (Pubitemid 23166739)
47. Joubert BM, Buckner FS, Matsuda SPT. Trypanosome and animal lanosterol synthases use different catalytic motifs. Org Lett 2001;3:1957-1960 (Pubitemid 33625254)
48. Buckner FS, Griffin JH, Wilson AJ, et al. Potent anti-Trypanosoma cruzi activities of oxidosqualene cyclase inhibitors. Antimicrob Agents Chemother 2001;45:1210-1215 (Pubitemid 32231002)
49. Hinshaw JC, Suh DY, Garnier P, et al. Oxidosqualene cyclase inhibitors as antimicrobial agents. J Med Chem 2003;46:4240-4243 (Pubitemid 37153005)
50. Oliaro-Bosso S, Ceruti M, Balliano G, et al. Analogs of squalene and oxidosqualene inhibit oxidosqualene cyclase of Trypanosoma cruzi expressed in Saccharomyces cerevisiae. Lipids 2005;40:1257-1262 (Pubitemid 43117850)
51. Oliaro-Bosso S, Viola F, Taramino S, et al. Inhibitory effect of umbelliferone aminoalkyl derivatives on oxidosqualene cyclases from Saccharomyces cerevisiae, Trypanosoma cruzi, and Pneumocystis carinii, Homo sapiens, and Arabidopsis thaliana:a structure-activity study. Chem Med Chem 2007;2:226-233
52. Galli U, Oliaro-Bosso S, Taramino S, et al. Design, synthesis, and biological evaluation of new (2E,6E)-10-(dimethylamino)-3,7-dimethyl-2,6- decadien-1-ol ethers as inhibitors of human and Trypanosoma cruzi oxidosqualene cyclase. Bioorg Med Chem Lett 2007;17:220-224 (Pubitemid 46001580)
53. McCabe RE, Remington JS, Araujo FG. In vitro and in vivo effects of itraconazole against Trypanosoma cruzi. Am J Trop Med Hyg 1986;35:280-284
54. McCabe RE, Remington JS, Araujo FG. Ketoconazole promotes parasitological cure of mice infected with Trypanosoma cruzi. Trans R Soc Trop Med Hyg 1987;81:613-615 (Pubitemid 17121107)
55. Brener Z, Cancado JR, Galvão LM, et al. An experimental and clinical assay with ketoconazole in the treatment of Chagas disease. Mem Inst Oswaldo Cruz 1993;88:149-153
56. Solari A, Saavedra H, Sepulveda C, et al. Successful treatment of Trypanosoma cruzi encephalitis in a patient with hemophilia and AIDS. Clin Inf Dis 1993;16:255-259 (Pubitemid 23047425)
57. Apt W, Arribada A, Zulantay I, et al. Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the results of clinical and parasitological examinations 11 years post-treatment. Ann Trop Med Parasitol 2005;99:733-741 (Pubitemid 41695614)
58. Urbina JA, Lazardi K, Aguirre T, et al. Antiproliferative effects and mechanism of action of ICI 195,739, a novel bis-triazole derivative, on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob Agents Chemother 1991;35:730-735
59. Urbina JA, Payares G, Sanoja C, et al. Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Int J Antimicrob Agents 2003;21:39-48 (Pubitemid 36043973)
60. Guedes PM, Urbina JA, de LM, et al. Activity of the new triazole derivative albaconazole against Trypanosoma (Schizotrypanum) cruzi in dog hosts. Antimicrob Agents Chemother 2004;48:4286-4292 (Pubitemid 39434888)
61. Corrales M, Cardozo R, Segura MA, et al. Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease. Antimicrob Agents Chemother 2005;49:1556-1560 (Pubitemid 40463388)
62. Molina J, Brener Z, Romanha AJ, et al. In vivo activity of the bis-triazole D0870 against drug-susceptible and drug-resistant strains of the protozoan parasite Trypanosoma cruzi. J Antimicrob Chemother 2000;46:137-140
63. Urbina JA, Payares G, Sanoja C, et al. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int J Antimicrobial Agents 2003;21:27-38
64. Urbina JA, Payares G, Contreras LM, et al. Antiproliferative effects and mechanism of action of SCH 56592 against Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Antimicrob Agents Chemother 1998;42:1771-1777 (Pubitemid 28311577)
65. Molina J, Martins-Filho O, Brener Z, et al. Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrob Agents Chemother 2000;44:150-155 (Pubitemid 30010686)
66. Ferraz ML, Gazzinelli RT, Alves RO, et al. The anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas' disease is less dependent on gamma interferon than that of benznidazole. Antimicrob Agents Chemother 2007;51:1359-1364 (Pubitemid 46586817)
67. Urbina JA, Docampo R. Specific chemotherapy of Chagas disease: controversies and advances. Trends Parasitol 2003;19:495-501 (Pubitemid 37329658)
68. Benaim G, Sanders JM, Garcia-Marchan Y, et al. Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J Med Chem 2006;49:892-899 (Pubitemid 43221637)
69. Buckner FS, Wilson AJ, White TC, et al. Induction of resistance to azole drugs in Trypanosoma cruzi. Antimicrob Agents Chemother 1998;42:3245-3250 (Pubitemid 28553748)
70. Buckner F, Yokoyama K, Lockman J, et al. A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. Proc Natl Acad Sci USA 2003;100:15149-15153 (Pubitemid 37518031)
71. Urbina JA, Vivas J, Lazardi K, et al. Antiproliferative effects of " 24(25) sterol methyl transferase inhibitors on Trypanosoma (Schizotrypanum) cruzi: in vitro and in vivo studies. Chemotherapy 1996;42:294-307
72. Magaraci F, Jimenez CJ, Rodrigues C, et al. Azasterols as inhibitors of sterol 24-methyltransferase in Leishmania species and Trypanosoma cruzi. J Med Chem 2003;46:4714-4727 (Pubitemid 37271620)
73. Orenes-Lorente SO, Rodrigues JCF, Jimenez CJ, et al. Novel azasterols as potential agents for treatment of leishmaniasis and trypanosomiasis. Antimicrob Agents Chemother 2004;48:2937-2950 (Pubitemid 38989159)
74. Gros L, Lorente SO, Jimenez CJ, et al. Evaluation of azasterols as anti-parasitics. J Med Chem 2006;49:6094-6103 (Pubitemid 44484953)
75. Cavalcanti DP, Thiry M, de Souza W, et al. The kinetoplast ultrastructural organization of endosymbiont-bearing trypanosomatids as revealed by deep-etching, cytochemical and immunocytochemical analysis. Histochem Cell Biol 2008; published online 10 June 2008, doi:10.1007/s00418-008-0450-7
76. Bray PG, Barrett MP, Ward SA, et al. Pentamidine uptake and resistance in pathogenic protozoa:past, present and future. Trends Parasitol 2003;19:232-239 (Pubitemid 36588598)
77. Werbovetz K. Diamidines as antitrypanosomal, antileishmanial and antimalarial agents. Curr Opin Investig Drugs 2006;7:147-157 (Pubitemid 43230911)
78. Wilson WD, Tanious FA, Mathis A, et al. Antiparasitic compounds that target DNA. Biochimie 2008;90:999-1014
79. Soeiro MNC, De Souza EM, Stephens CE, et al. Aromatic diamidines as antiparasitic agents. Expert Opin Investig Drugs 2005;14:957-972 (Pubitemid 41131649)
80. Wilson WD, Nguyen B, Tanious FA, et al. Dications that target the DNA minor groove:compound design and preparation, DNA interactions, cellular distribution and biological activity. Curr Med Chem Anticancer Agents 2005;5:389-408 (Pubitemid 40974812)
81. Mathis AM, Holman JL, Sturk LM, et al. Accumulation and intracellular distribution of antitrypanosomal diamidine compounds DB75 and DB820 in African trypanosomes. Antimicrob Agents Chemother 2006;50:2185-2191 (Pubitemid 43807541)
82. De Souza EM, Melo G, Boykin DW, et al. Trypanocidal activity of the phenyl-substituted analogue of furamidine DB569 against Trypanosoma cruzi infection in vivo. J Antimicrob Chemother 2006;58:610-614 (Pubitemid 44288126)
83. Singh G, Dey CS. Induction of apoptosis-like cell death by pentamidine and doxorubicin through differential inhibition of topoisomerase II in arsenite-resistant Leishmania donovani. Acta Trop 2007;103:172-185 (Pubitemid 47301771)
84. Soeiro MNC, De Souza EM, Boykin DW. Antiparasitic activity of aromatic diamidines and their patented literature. Expert Opin Ther Patents 2007;17:1-13
85. Soeiro MNC, de Castro SL, Souza EM, et al. Diamidines activity upon trypanosomes:the state of the art. Curr Mol Pharmacol 2008;1:151-161
86. De Souza EM, Lansiaux A, Bailly C, et al. Phenyl substitution of furamidine markedly potentiates its antiparasitic activity against Trypanosoma cruzi and Leishmania amazonensis. Biochem Pharmacol 2004;68:593-600 (Pubitemid 38953440)
87. De Souza EM, Menna-Barreto R, Araújo-Jorge TC, et al. Antiparasitic activity of aromatic diamidines is related to apoptosis-like death in Trypanosoma cruzi. Parasitology 2006;133:75-79 (Pubitemid 43886439)
88. De Souza EM, Oliveira GM, Soeiro MNC. Electrocardiographic findings in acutely and chronically Trypanosoma cruzi-infected mice treated by a phenyl-substituted analogue of furamidine DB569. Drug Targets Insights 2007;2:61-69
89. Silva CF, Batista MM, Batista DG, et al. In vitro and in vivo studies of the trypanocidal activity of a diarylthiophene diamidine against Trypanosoma cruzi. Antimicrob Agents Chemother 2008;52:3307-3314
90. Stephens CE, Tanious F, Kim S, et al. Diguanidino and "reversed" diamidino 2,5-diarylfurans as antimicrobial agents. J Med Chem 2001;44:1741-1748 (Pubitemid 32852181)
91. Silva CF, Meuser MB, Mota RA, et al. Activity of "reversed" diamidines against Trypanosoma cruzi in vitro. Biochemical Pharmacol 2007;73:1939-1946
92. Stephens CE, Brun R, Salem MM, et al. The activity of diguanidino and "reversed" diamidino 2,5-diarylfurans versus Trypanosoma cruzi and Leishmania donovani. Bioorg Med Chem Lett 2003;13:2065-2069 (Pubitemid 36638411)
93. Messeder JC, Tinoco W, Figueroa-Villar JD, et al. Aromatic guanylhydrazones:Synthesis, structural studies and in vitro activity against Trypanosoma cruzi. Bioorganic Med Chem Let 1995;24:3079-3084
94. Silva CF, Meuser MB, De Souza EM, et al. Cellular effects of reversed amidines on Trypanosoma cruzi. Antimicrob Agents Chemother 2007;51:3803-3809 (Pubitemid 350057774)
95. Krauth-Siegel RL, Comini MA. Redox control in trypanosomatids, parasitic protozoa with trypanothione-based thiol metabolism. Biochim Biophys Acta 2008;1780:1236-1248
96. Fairlamb AH, Cerami A. Metabolism and functions of trypanothione in the Kinetoplastida. Annu Rev Microbiol 1992;46:695-729
97. Krauth-Siegel RL, Enders B, Henderson GB, et al. Trypanothione reductase from Trypanosoma cruzi. Purification and characterization of the crystalline enzyme. Eur J Biochem 1987;164:123-128 (Pubitemid 17053675)
98. Henderson GB, Ulrich P, Fairlamb AH, et al. "Subversive" substrates for the enzyme trypanothione disulfide reductase: alternative approach to chemotherapy of Chagas disease. Proc Natl Acad Sci USA 1988;85:5374-5378
99. Blumenstiel K, Schoeneck R, Yardley V, et al. Nitrofuran drugs as common subversive substrates of Trypanosoma cruzi lipoamide dehydrogenase and trypanothione reductase. Biochem Pharmacol 1999;58:1791-1799 (Pubitemid 29505420)
100. Salmon-Chemin L, Buisine E, Yardley V, et al. 2- and 3-substituted 1,4-naphthoquinone derivatives as subversive substrates of trypanothione reductase and lipoamide dehydrogenase from Trypanosoma cruzi: synthesis and correlation between redox cycling activities and in vitro cytotoxicity. J Med Chem 2001;44:548-565 (Pubitemid 32156097)
101. Khan MO, Austin SE, Chan C, et al. Use of an additional hydrophobic binding site, the Z site, in the rational drug design of a new class of stronger trypanothione reductase inhibitor, quaternary alkylammonium phenothiazines. J Med Chem 2000;43:3148-3156 (Pubitemid 30627549)
102. Augustyns K, Amssoms K, Yamani A, et al. Trypanothione as a target in the design of antitrypanosomal and antileishmanial agents. Curr Pharm Des 2001;7:1117-1141 (Pubitemid 32640573)
103. Otero L, Vieites M, Boiani L, et al. Novel antitrypanosomal agents based on palladium nitrofurylthiosemicarbazone complexes:DNA and redox metabolism as potential therapeutic targets. J Med Chem 2006;49:3322-3331 (Pubitemid 43830530)
104. Galarreta BC, Sifuentes R, Carrillo AK, et al. The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors. Bioorg Med Chem 2008;16:6689-6695
105. Cota BB, Rosa LH, Fagundes EM, et al. A potent trypanocidal component from the fungus Lentinus strigosus inhibits trypanothione reductase and modulates PBMC proliferation. Mem Inst Oswaldo Cruz 2008;103:263-270 (Pubitemid 351946121)
106. Parveen S, Khan MO, Austin SE, et al. Antitrypanosomal, antileishmanial, and antimalarial activities of quaternary arylalkylammonium 2-amino-4- chlorophenyl phenyl sulfides, a new class of trypanothione reductase inhibitor, and of N-acyl derivatives of 2-amino-4-chlorophenyl phenyl sulfide. J Med Chem 2005;48:8087-8097 (Pubitemid 41798439)
107. Schmidt A, Krauth-Siegel RL. Enzymes of the trypanothione metabolism as targets for antitrypanosomal drug development. Curr Top Med Chem 2002;2:1239-1259
108. Sant'anna C, Parussini F, Lourenço D, et al. All Trypanosoma cruzi developmental forms present lysosome-related organelles. Histochem Cell Biol 2008; published online 12 August 2008, doi:10.1007/s00418-008-0486-8
109. Chung JY, Bae YA, Na BK, et al. Cysteine protease inhibitors as potential antiparasitic agents. Expert Opin Ther Patents 2005;15:995-1007 (Pubitemid 41167617)
110. González FV, Izquierdo J, Rodríguez S, et al. Dipeptidyl-α,β-epoxyesters as potent irreversible inhibitors of the cysteine proteases cruzain and rhodesain. Bioorg Med Chem Lett 2007;17:6697-6700 (Pubitemid 350061325)
111. Chen YT, Lira R, Hansell E, et al. Synthesis of macrocyclic trypanosomal cysteine protease inhibitors. Bioorg Med Chem Lett 2008;18:5860-5863
112. Engel JC, Doyle PS, Hsieh I, et al. Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J Exp Med 1998;188:725-734 (Pubitemid 28387935)
113. Barr SC, Warner KL, Kornreic BG, et al. A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. Antimicrob Agents Chemother 2005;49:5160-5161 (Pubitemid 41778941)
114. Doyle PS, Zhou YM, Engel JC, et al. A cysteine protease inhibitor cures Chagas disease in an immunodeficient murine model of infection. Antimicrob Agents Chemother 2007;51:3932-3939 (Pubitemid 350057791)
115. Du X, Hansell E, Engel JC, et al. Aryl ureas represent a new class of anti-trypanosomal agents. Chem Biol 2000;7:733-742
116. Rodrigues CR, Flaherty TM, Springer C, et al. CoMFA and HQSAR of acylhydrazide cruzain inhibitors. Bioorg Med Chem Lett 2002;12:1537-1541 (Pubitemid 34521930)
117. Choe Y, Brinen LS, Price MS, et al. Development of α-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease. Bioorg Med Chem 2005;13:2141-2156 (Pubitemid 40261134)
118. Brak K, Doyle PS, McKerrow JH, et al. Identification of a new class of nonpeptidic inhibitors of cruzain. J Am Chem Soc 2008;130:6404-6410 (Pubitemid 351706101)
119. Fothergill-Gilmore LA, Michels PAM. Evolution of glycolysis. Prog Biophys Mol Biol 1993;59:105-235 (Pubitemid 223010340)
120. Périé J, Albuquerque C, Blonski C, et al. Rational concepts and the study of active molecules against various trypanosomiases. Bull Soc Pathol Exot 1994;87:353-361
121. Lakhdar-Ghazal F, Blonski C, Wilson M, et al. Glycolysis and proteases as targets for the design of new anti-trypanosome drugs. Curr Top Med Chem 2002;2:439-456
122. Souza DH, Garratt RC, Araujo AP, et al. Trypanosoma cruzi glycosomal glyceraldehyde-3-phosphate dehydrogenase: structure, catalytic mechanism and targeted inhibitor design. FEBS Lett 1998;424:131-135 (Pubitemid 28135298)
123. Bressi JC, Verlinde CL, Aronov AM, et al. Adenosine analogues as selective inhibitors of glyceraldehyde-3-phosphate dehydrogenase of trypanosomatidae via structure-based drug design. J Med Chem 2001;44:2080-2093 (Pubitemid 32861769)
124. Tomazela DM, Pupo MT, Passador EA, et al. Pyrano chalcones and a flavone from Neoraputia magnifica and their Trypanosoma cruzi glycosomal glyceraldehyde-3-phosphate dehydrogenase-inhibitory activities. Phytochemistry 2000;55:643-651
125. De Marchi AA, Castilho MS, Nascimento PG, et al. New 3-piperonylcoumarins as inhibitors of glycosomal glyceraldehyde-3-phosphate dehydrogenase (gGAPDH) from Trypanosoma cruzi. Bioorg Med Chem 2004;12:4823-4833 (Pubitemid 39164390)
126. Hudock MP, Sanz-Rodriguez CE, Song Y, et al. Inhibition of Trypanosoma cruzi hexokinase by bisphosphonates. J Med Chem 2006;49:215-223 (Pubitemid 43077335)
127. Igoillo-Esteve M, Maugeri D, Stern AL, et al. The pentose phosphate pathway in Trypanosoma cruzi: a potential target for the chemotherapy of Chagas disease. An Acad Bras Cienc 2007;79:649-663 (Pubitemid 350248758)
128. Maugeri DA, Cazzulo JJ. The pentose phosphate pathway in Trypanosoma cruzi. FEMS Microbiol Lett 2004;234:117-123 (Pubitemid 38515760)
129. Ullman B, Carter D. Molecular and biochemical studies on the hypoxanthine-guanine phosphoribosyltransferases of the pathogenic haemoflagellates. Int J Parasitol 1997;27:203-213 (Pubitemid 27139711)
130. Freymann DM, Wenck MA, Engel JC, et al. Efficient identification of inhibitors targeting the closed active site conformation of the HPRT from Trypanosoma cruzi. Chem Biol 2000;7:957-968 (Pubitemid 32046424)
131. Marr JJ. Purine analogs as chemotherapeutic agents in leishmaniasis and American trypanosomiasis. J Lab Clin Med 1991;118:111-119
132. Gobbi P, Lo Presti MS, Fernandez AR, et al. Allopurinol is effective to modify the evolution of Trypanosoma cruzi infection in mice. Parasitol Res 2007;101:1459-1462 (Pubitemid 47389441)
133. Rassi A, Luquetti AO, Rassi A Jr, et al. Specific treatment for Trypanosoma cruzi: lack of efficacy of allopurinol in the human chronic phase of Chagas disease. Am J Trop Med Hyg 2007;76:58-61 (Pubitemid 351627803)
134. Eakin AE, Guerra A, Focia PJ, et al. Hypoxanthine phosphoribosyltransferase from Trypanosoma cruzi as a target for structure-based inhibitor design:crystallization and inhibition studies with purine analogs. Antimicrob Agents Chemother 1997;41:1686-1692 (Pubitemid 27339868)
135. Reche P, Arrebola R, Santi DV, et al. Expression and characterization of the Trypanosoma cruzi dihydrofolate reductase domain. Mol Biochem Parasitol 1996;76:175-185 (Pubitemid 26122733)
136. Zuccotto F, Zvelebil M, Brun R, et al. Novel inhibitors of Trypanosoma cruzi dihydrofolate reductase. Eur J Med Chem 2001;36:395-405 (Pubitemid 32635212)
137. Gilbert IH. Inhibitors of dihydrofolate reductase in leishmania and trypanosomes. Bba Mol Basis Dis 2002;1587:249-257 (Pubitemid 34655793)
138. Pez D, Leal I, Zuccotto F, et al. 2,4-Diaminopyrimidines as inhibitors of leishmanial and trypanosomal dihydrofolate reductase. Bioorg Med Chem 2003;11:4693-4711
139. Senkovich O, Bhatia V, Garg N, et al. Lipophilic antifolate trimetrexate is a potent inhibitor of Trypanosoma cruzi: prospect for chemotherapy of Chagas' disease. Antimicrob Agents Chemother 2005;49:3234-3238 (Pubitemid 41065077)
140. DNDi home page. Available from: www.dndi.org
141. Courtney R, Pai S, Laughlin M, et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003;47:2788-2795 (Pubitemid 37040249)
142. Midgley I, Fitzpatrick K, Taylor LM, et al. Pharmacokinetics and metabolism of the prodrug DB289 (2,5-bis[4-(N-methoxyamidino)phenyl]furan monomaleate) in rat and monkey and its conversion to the antiprotozoal/